用户名/邮箱
登录密码
验证码
看不清?换一张
您好,欢迎访问! [ 登录 | 注册 ]
您的位置:首页 - 最新资讯
World's most-used Covid-19 vaccine being tested on Omicron, says Sinovac
2021-12-13 00:00:00.0     海峡时报-亚洲     原网页

       

       BEIJING (BLOOMBERG) - China's Sinovac Biotech, whose coronavirus vaccine is the most widely used globally with 2.3 billion doses shipped out, has said it is testing its inactivated shot against the Omicron variant in a number of laboratory studies.

       The update comes as Pfizer, which makes the world's second-most used vaccine with BioNTech, said that neutralising antibody levels fell against Omicron compared with the original strain of the virus, but that a booster shot should provide people with sufficient protection.

       Beijing-based Sinovac is currently undertaking the same sort of study that Pfizer did, which uses a pseudovirus - a genetically modified stand-in for the real pathogen, said a company representative on Thursday (Dec 9).

       That will provide the first and quickest insight into how much potency its shot still retains for Omicron.

       The company declined to say when it would be able to release results.

       How well Sinovac's shot holds up against Omicron is a question of significant consequence for much of the developing world reliant on the Chinese vaccine, which is easier to store and administer than the messenger RNA immunisations manufactured by Pfizer-BioNTech and Moderna.

       While still highly effective at warding off serious illness and death, it protects much less against transmission and symptomatic disease than the mRNA vaccines for the original strain of the virus and for the Delta variant.

       The company said it has also obtained the Omicron variant and is studying how well vaccine-induced antibodies can respond to the live virus.

       Concerns are swirling globally that Omicron could deal the world a bigger blow than even Delta, and the World Health Organisation has cautioned that it could fuel surges with "severe consequences".

       But a jump in cases in South Africa in the wake of the variant's emergence has not yet overwhelmed hospitals, leading to some optimism that it may only cause mostly mild illness.

       More on this topic

       Related Story

       China grants emergency approval for its first Covid-19 drug

       Related Story

       China eyes anti-Covid-19 oral drug to boost image, reopen borders

       Related Stories:

       Related Story

       HK researchers develop steel that kills 99% of Covid-19 virus within hours

       Related Story

       Will I lose fully vaccinated status if I don't get third Sinovac, Sinopharm dose?

       Related Story

       Trump's blood oxygen level in Covid-19 bout was dangerously low, former aide says in book

       Related Story

       Omicron's spread across hotel hall in Hong Kong highlights transmission worry

       Related Story

       Top Covid-19 expert hints at how China may return to 'normality'

       Related Story

       South Korea's Covid-19 rules put some vaccinated foreigners in limbo

       Related Story

       Inside South Africa's effort to halt dangerous Covid-19 mutations

       Related Story

       Lessons from travelling in a Covid-19-stricken world

       Related Story

       The week that Covid-19 sucker punched the world

       Related Story

       Pfizer or Moderna booster - which is more effective? Here's what an MOH study shows

       Join ST's Telegram channel here and get the latest breaking news delivered to you.

       Topics:

       More Whatsapp Linkedin FB Messenger Telegram Reddit WeChat Pinterest Print Copy permalink https://str.sg/3xyH

       


标签:综合
关键词: Covid     Pfizer     Moderna     coronavirus vaccine     variant     Omicron     Story     China's Sinovac Biotech    
滚动新闻